Biofil Chemicals & Pharmaceuticals Ltd
Incorporated in 1993, Biofil Chemicals and Pharmaceuticals Ltd manufactures pharmaceutical bulk drugs[1]
- Market Cap ₹ 74.7 Cr.
- Current Price ₹ 45.9
- High / Low ₹ 92.0 / 40.4
- Stock P/E 125
- Book Value ₹ 11.3
- Dividend Yield 0.00 %
- ROCE 4.94 %
- ROE 4.00 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company's working capital requirements have reduced from 106 days to 73.4 days
Cons
- Stock is trading at 4.06 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 11.6% over past five years.
- Company has a low return on equity of 3.84% over last 3 years.
- Earnings include an other income of Rs.0.48 Cr.
- Company has high debtors of 301 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6.01 | 7.17 | 5.86 | 13.17 | 13.45 | 12.36 | 23.13 | 29.69 | 35.75 | 22.38 | 30.04 | 40.04 | 40.25 | |
5.00 | 6.21 | 5.12 | 12.30 | 10.84 | 11.43 | 22.11 | 27.87 | 34.15 | 21.05 | 28.88 | 39.23 | 39.55 | |
Operating Profit | 1.01 | 0.96 | 0.74 | 0.87 | 2.61 | 0.93 | 1.02 | 1.82 | 1.60 | 1.33 | 1.16 | 0.81 | 0.70 |
OPM % | 16.81% | 13.39% | 12.63% | 6.61% | 19.41% | 7.52% | 4.41% | 6.13% | 4.48% | 5.94% | 3.86% | 2.02% | 1.74% |
0.06 | 0.06 | 0.46 | 0.53 | 0.14 | 0.10 | 0.10 | 0.17 | 0.80 | 0.15 | 0.10 | 0.49 | 0.48 | |
Interest | 0.19 | 0.15 | 0.21 | 0.15 | 0.16 | 0.15 | 0.16 | 0.12 | 0.07 | 0.04 | 0.04 | 0.04 | 0.05 |
Depreciation | 0.21 | 0.22 | 0.25 | 0.26 | 0.28 | 0.30 | 0.37 | 0.41 | 0.41 | 0.43 | 0.43 | 0.40 | 0.38 |
Profit before tax | 0.67 | 0.65 | 0.74 | 0.99 | 2.31 | 0.58 | 0.59 | 1.46 | 1.92 | 1.01 | 0.79 | 0.86 | 0.75 |
Tax % | 19.40% | 20.00% | 20.27% | 20.20% | 22.51% | 20.69% | 20.34% | 17.81% | 34.90% | 31.68% | 29.11% | 17.44% | |
0.54 | 0.52 | 0.59 | 0.78 | 1.79 | 0.47 | 0.48 | 1.21 | 1.24 | 0.70 | 0.56 | 0.71 | 0.60 | |
EPS in Rs | 0.33 | 0.32 | 0.36 | 0.48 | 1.10 | 0.29 | 0.29 | 0.74 | 0.76 | 0.43 | 0.34 | 0.44 | 0.36 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 19% |
5 Years: | 12% |
3 Years: | 4% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | 3% |
5 Years: | 8% |
3 Years: | -17% |
TTM: | -9% |
Stock Price CAGR | |
---|---|
10 Years: | 28% |
5 Years: | 26% |
3 Years: | -10% |
1 Year: | -34% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 5% |
3 Years: | 4% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
Reserves | -8.91 | -8.41 | -7.86 | -5.37 | -3.58 | -3.11 | -2.62 | -1.39 | -0.14 | 0.56 | 1.03 | 1.93 | 2.12 |
2.79 | 2.87 | 2.98 | 1.37 | 1.43 | 1.56 | 1.64 | 1.19 | 0.43 | 0.46 | 0.52 | 0.44 | 0.46 | |
3.35 | 3.87 | 2.36 | 11.87 | 7.72 | 9.44 | 8.93 | 26.30 | 16.68 | 1.44 | 13.58 | 28.44 | 23.19 | |
Total Liabilities | 13.50 | 14.60 | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 42.04 |
9.17 | 9.17 | 9.06 | 8.98 | 9.16 | 9.25 | 10.29 | 10.09 | 9.78 | 9.42 | 9.00 | 8.62 | 8.43 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
4.33 | 5.43 | 4.69 | 15.16 | 12.68 | 14.91 | 13.93 | 32.28 | 23.46 | 9.31 | 22.40 | 38.46 | 33.61 | |
Total Assets | 13.50 | 14.60 | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 42.04 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.12 | 0.21 | 0.01 | 0.14 | 0.71 | 0.46 | 1.26 | 0.89 | 1.11 | -0.22 | -0.11 | 2.39 | |
-0.30 | -0.24 | -0.17 | -0.19 | -0.48 | -0.38 | -1.41 | -0.21 | -0.10 | -0.07 | -0.01 | -0.02 | |
0.30 | 0.07 | 0.11 | 0.10 | -0.11 | -0.02 | -0.08 | -0.57 | -0.83 | -0.01 | 0.02 | -0.12 | |
Net Cash Flow | -0.12 | 0.04 | -0.05 | 0.05 | 0.13 | 0.06 | -0.24 | 0.12 | 0.18 | -0.30 | -0.11 | 2.25 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 202.85 | 208.72 | 227.35 | 387.45 | 311.00 | 383.31 | 189.84 | 365.25 | 175.81 | 116.94 | 249.08 | 301.10 |
Inventory Days | 31.15 | 20.53 | 15.99 | 3.46 | 7.29 | 38.11 | 21.73 | 24.37 | 48.85 | 24.20 | 16.11 | 24.81 |
Days Payable | 302.71 | 276.79 | 198.49 | 400.98 | 304.52 | 341.46 | 156.66 | 373.80 | 178.39 | 11.25 | 168.39 | 268.08 |
Cash Conversion Cycle | -68.71 | -47.54 | 44.85 | -10.07 | 13.76 | 79.95 | 54.90 | 15.82 | 46.27 | 129.88 | 96.80 | 57.83 |
Working Capital Days | 51.62 | 70.25 | 137.65 | 86.47 | 126.46 | 150.90 | 76.69 | 70.32 | 68.51 | 132.76 | 110.57 | 73.38 |
ROCE % | 8.83% | 7.66% | 8.59% | 9.64% | 18.72% | 5.06% | 5.00% | 10.08% | 12.20% | 6.20% | 4.73% | 4.94% |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
22 Apr - Biofil Chemicals confirms non-applicability of SEBI large corporate debt issuance rules as of March 31, 2025.
-
Announcement Under Regulation 30 (5) Of SEBI (LODR) Regulation , 2015
19 Apr - Appointment of Mr. Apoorv Jain as Company Secretary & Compliance Officer and KMP authorisation update
-
Announcement under Regulation 30 (LODR)-Change in Management
19 Apr - Appointment of Apoorv Jain as Company Secretary and Compliance Officer
-
Appointment of Company Secretary and Compliance Officer
19 Apr - Appointment of Apoorv Jain as Company Secretary & Compliance Officer
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Apr - Certificate under Regulation 74(5) for Q1 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
Company deals in manufacturing and trading of pharmaceutical and also manufactures plastic products required for packing pharmaceutical and other plastic products. Further, it also deals in providing job work facility in respect of manufacturing of pharmaceuticals drugs via 2 units viz. Pharmaceutical Division & Chemicals Division.